10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Pitcairn Co.

Pitcairn Co. reduced its position in 10x Genomics, Inc. (NASDAQ:TXG) by 18.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,648 shares of the company’s stock after selling 1,259 shares during the quarter. Pitcairn Co.’s holdings in 10x Genomics were worth $212,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in 10x Genomics by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock valued at $341,581,000 after acquiring an additional 90,204 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in 10x Genomics by 58.6% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,621,778 shares of the company’s stock valued at $135,925,000 after acquiring an additional 1,338,248 shares in the last quarter. Nikko Asset Management Americas Inc. grew its position in shares of 10x Genomics by 58.6% during the first quarter. Nikko Asset Management Americas Inc. now owns 3,621,778 shares of the company’s stock worth $135,780,000 after buying an additional 1,338,248 shares in the last quarter. Brown Capital Management LLC grew its position in shares of 10x Genomics by 14.5% during the fourth quarter. Brown Capital Management LLC now owns 3,527,297 shares of the company’s stock worth $197,388,000 after buying an additional 446,192 shares in the last quarter. Finally, Venrock Management VI LLC acquired a new position in shares of 10x Genomics during the fourth quarter worth about $117,894,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,087 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $99,314.10. Following the completion of the sale, the insider now owns 350,055 shares of the company’s stock, valued at $8,506,336.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other 10x Genomics news, insider Benjamin J. Hindson sold 4,087 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $99,314.10. Following the completion of the sale, the insider now owns 350,055 shares of the company’s stock, valued at $8,506,336.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 4,877 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total value of $118,511.10. Following the completion of the transaction, the chief executive officer now owns 889,641 shares of the company’s stock, valued at approximately $21,618,276.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,900 shares of company stock valued at $289,170. 10.03% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Canaccord Genuity Group lowered their price objective on 10x Genomics from $50.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday. Barclays lowered their price target on 10x Genomics from $36.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, June 28th. JPMorgan Chase & Co. downgraded 10x Genomics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $40.00 to $20.00 in a report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft cut 10x Genomics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $55.00 to $25.00 in a research note on Wednesday, July 10th. Finally, Wolfe Research reissued a “peer perform” rating on shares of 10x Genomics in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $36.29.

10x Genomics Stock Up 2.6 %

Shares of NASDAQ TXG opened at $20.44 on Friday. The stock has a fifty day moving average price of $20.31 and a 200 day moving average price of $32.25. 10x Genomics, Inc. has a 1-year low of $15.28 and a 1-year high of $63.57.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Tuesday, April 30th. The company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). 10x Genomics had a negative return on equity of 30.85% and a negative net margin of 42.20%. The firm had revenue of $141.01 million during the quarter, compared to the consensus estimate of $142.24 million. During the same period last year, the company earned ($0.44) earnings per share. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. As a group, sell-side analysts expect that 10x Genomics, Inc. will post -1.53 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.